The CCR5 antagonist maraviroc causes remission of ... | 合法藥品大搜索

CCR5 receptor antagonists are a class of small molecules that antagonize the CCR5 receptor. The C-C motif chemokine receptor CCR5 is involved in the process ... Read More

由 S Sayana 著作 · 2009 · 被引用 66 次 — Maraviroc is a small molecule and a member of a new class of antiretroviral compounds known as CCR5 antagonists, which block R5-tropic HIV entry into CD4 ... Read More

由 M Baba 著作 · 1999 · 被引用 1009 次 — The beta-chemokine receptor CCR5 is considered to be an attractive target for inhibition of macrophage-tropic (CCR5-using or R5) HIV-1 replication because ... Read More

由 GG Xu 著作 · 2014 · 被引用 29 次 — Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applications. Curr Top Med Chem. 2014;14(13):1504-14. doi: ... Read More

由 M Westby 著作 · 2005 · 被引用 158 次 — The current leading CCR5 antagonists in clinical development include maraviroc (UK-427,857, Pfizer), aplaviroc (873140, GlaxoSmithKline) and vicriviroc (SCH-D, ... Read More

由 H Huang 著作 · 2020 · 被引用 11 次 — In this study, we blocked the CCR5 receptor by the FDA approved antagonist maraviroc (MVC) in Suit2-007 and MIA-PaCa-2 human PDAC cells. The ... Read More

由 MB Kim 著作 · 2016 · 被引用 28 次 — Surprisingly, the only CCR5 antagonist currently in advanced clinical trials for the treatment of chronic HIV infection is Cenicriviroc (TAK-652, 51). In ... Read More

由 PKS Rao 著作 · 2009 · 被引用 27 次 — Maraviroc is a CCR5 antagonist with potent in vitro and in vivo anti-HIV-1 activity, recently approved by the FDA for treatment-experienced patients with R5- ... Read More

由 OS Latinovic 著作 · 2019 · 被引用 2 次 — At present, the small-molecule CCR5 antagonist Maraviroc (MVC) is the only licensed CCR5 inhibitor on the market (Pfizer, 2007) [39] and is approved for use in ... Read More

Maraviroc is the first CCR5 receptor antagonist licensed for the treatment of HIV infection. Co-receptor tropism should be determined prior to using maraviroc ... Read More